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https://doi.org/10.1016/j.celrep.2019.11.041SUMMARY
To understand the molecular mechanisms that
mediate the anti-hepatitis B virus (HBV) effect
of interferon (IFN) therapy, we conduct high-
throughput bimolecular fluorescence complemen-
tation screening to identify potential physical
interactions between the HBx protein and 145 IFN-
stimulated genes (ISGs). Seven HBx-interacting
ISGs have consistent and significant inhibitory ef-
fects on HBV replication, among which TRIM5g sup-
presses HBV replication by promoting K48-linked
ubiquitination and degradation of the HBx protein
on the K95 ubiquitin site. The B-Box domain of
TRIM5g under overexpression conditions is suffi-
cient to trigger HBx degradation and is responsible
both for interacting with HBx and recruiting
TRIM31, which is an ubiquitin ligase that triggers
HBx ubiquitination. High expression levels of
TRIM5g in IFN-a-treated HBV patients might indicate
a better therapeutic effect. Thus, our studies identify
a crucial role for TRIM5g and TRIM31 in promoting
HBx degradation, which may facilitate the develop-
ment of therapeutic agents for the treatment of pa-
tients with IFN-resistant HBV infection.INTRODUCTION
Chronic hepatitis B virus (HBV) infection remains a major public
health threat. It is associated with increasing rates of hepatocellu-
lar carcinoma (HCC) worldwide. According to the World Health
Organization (WHO), 2 billion people are infected with HBV, of
which over 240million are chronically infected,which places these
people at a high risk for development of liver cirrhosis and eventu-This is an open access article under the CC BY-Nally HCC. Although a vaccine has been available for HBV for
almost 30 years, nearly 1 million people die each year due to
HBV-related complications, including severe chronic hepatitis,
cirrhosis, and primary liver cancer (Mutimer and Lok, 2012).
HBV is a partially double-stranded DNA virus belonging to the
Hepadnaviridae family (Evans and Seeger, 2007). After entry into
host cells, the viral genome translocates to the nucleus and is
converted to covalently closed circular DNA (cccDNA), which
is the transcription template for all HBV viral RNAs. Currently
available HBV therapeutics (including INF-a and antiviral drugs)
fail to eradicate the cccDNA reservoir from infected hepatocytes,
despite suppressing replication of new viral DNA. Consequently,
the persistent cccDNA results in post-treatment viral rebound
(Nassal, 2015; Revill and Locarnini, 2016).
The HBV-encoded regulatory protein hepatitis B virus X pro-
tein (HBx) stimulates HBV gene expression from the cccDNA
template; however, the mechanism by which HBx facilitates
HBV replication is not clear (Keasler et al., 2007). HBx is a 154-
amino-acid protein with an N-terminal negative regulatory
domain and C-terminal transactivation or coactivation domain.
HBx interacts with several cellular proteins, and its role in virus
replication may be mediated through these interactions. The
best-characterized HBx binding partner is the damage-specific
DNA binding protein 1 (DDB1) (Sitterlin et al., 1997). The interac-
tion between HBx and DDB1 is conserved among the HBx pro-
teins from all mammalian hepadnaviruses and woodchuck hep-
atitis virus (WHV) X protein (Sitterlin et al., 1997). This binding is
essential for HBV replication (Hodgson et al., 2012). It was
recently reported that an HBx-DDB1-CUL4-ROC1 E3 ligase
complex targets the SMC5/6 complex to enhance HBV gene
expression from episomal cccDNA (Mitra and Guo, 2016; Mur-
phy et al., 2016).
IFN therapy is an approved treatment modality for chronic
HBV infection. However, the poor response and substantial
side effects associated with this treatment impact its clinical util-
ity (Tan et al., 2018b). HBV has been shown to inhibit IFN-stimu-
lated genes (ISGs) and even the production of IFN in infectedCell Reports 29, 3551–3563, December 10, 2019 3551
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
patients (Khan et al., 2016; Lim et al., 2017; Liu et al., 2015; Xu
et al., 2016). However, the mechanism of HBV-mediated inhibi-
tion of ISGs is poorly understood. Therefore, unraveling the mo-
lecular mechanisms of the interaction between IFN andHBV dur-
ing the course of viral infection is a key imperative, which may
help improve the efficacy of IFN therapy.
The induction of the type I IFN family (IFN-a, -b, -ε, -k,
and -u) is perhaps the most important innate immune response
to viral infection. Since its discovery in 1957, type I IFN has
been recognized as the major antiviral cytokine in vertebrates
(Hayes and Chayama, 2017; Isaacs and Lindenmann, 1957).
Most nucleated vertebrate cells are able to both produce and
respond to type I IFN. The antiviral function of type I IFN is
carried out through its binding to the type I IFN receptor
(IFNAR1), activation of the JAK/STAT pathway, and subsequent
induction of about 300 ISGs (Ivashkiv and Donlin, 2014), which
can inhibit different stages of the viral life cycle (Chen et al.,
2014; Liu et al., 2013). Some ISGs have already been shown
to inhibit HBV replication. For example, TRIM22 was shown
to confer antiviral immunity against HBV by its inhibitory effect
on viral core promoter activity (Gao et al., 2009). We reported
that TRIM14 inhibited HBV replication by blocking the formation
of the DDB1-HBx-Smc complex (Xu et al., 2019), and
APOBEC3A/B was shown to play a critical role in the degrada-
tion of nuclear HBV cccDNA (Lucifora et al., 2014). Unfortu-
nately, there is currently no effective treatment for patients
who respond poorly to IFN therapy. Therefore, characterization
of the ISGs that specifically modulate HBV infection and repli-
cation is a key imperative. In the present study, we conducted a
high-throughput bimolecular fluorescence complementation
(BiFC) assay screen and identified 41 out of 145 ISG products
that interact with the HBx protein. The interaction of 26 ISGs
was further confirmed by co-immunoprecipitation (coIP). Seven
HBx-interacting ISGs (GBP2, PVRL4, CBFb, TRIM38, TRIM5g,
TRIM25, and Gadd45g) showed strong inhibitory effects on
HBV replication. The TRIM5 family was famous since the dis-
covery of TRIM5a as a blocking factor of HIV infection by bind-
ing to the capsid that surrounds and protects the viral core
(Stremlau et al., 2004). TRIM5 proteins share a common tripar-
tite motif, which consists of RING, B-box 2, and coiled-coil do-
mains, followed by SPRY, a C-terminal domain that is required
for capsid recognition (Ganser-Pornillos and Pornillos, 2019).
Interestingly, TRIM5g does not have a SPRY domain. Here,
we further narrowed our investigation to TRIM5g anti-HBV
function and showed that the BBox domain of TRIM5g is suffi-
cient for interaction with HBx and for triggering the HBx-K48
ubiquitination and degradation. Furthermore, we showed that
this process likely requires the E3 ubiquitin ligase activity of
TRIM31, recruited by TRIM5g. More importantly, we found
that high induction of TRIM5g in the IFN-a-treated HBV patients
predicts a much better outcome. Our study, therefore, high-
lights a critical role for TRIM5g and TRIM31 in promoting HBx
degradation and reveals another mechanism that might impact
the effectiveness of IFN therapy in HBV-infected patients. In
addition, our study suggests that TRIM5g may serve as a
biomarker to predict the response to IFN-a therapy and that
BBOX may be a potential candidate for the development of
therapeutic agents that target HBx.3552 Cell Reports 29, 3551–3563, December 10, 2019RESULTS
Identification of 26 ISG Proteins That Interact with the
HBx Protein by BiFC and CoIP Assays
We hypothesized that ISGs can inhibit HBV viral infection and
replication through interactions with individual viral proteins. A
recent study researched how ISGs inhibit viruses by overexpres-
sion of about 300 individual ISGs (Liu et al., 2012). HBx is an
indispensable transcriptional factor in the HBV life cycle, which
interacts with multiple proteins and promotes HBV replication
(Keasler et al., 2007). In the present study, we used a BiFC assay
to screen 145 ISG proteins for interaction with HBx. This assay
involves transient expression of HBx fused with the N-terminal
portion of the yellow fluorescent protein (YFP) and cellular
ISGs fused to the C terminus of YFP (Figure 1A). Interaction be-
tween viral proteins and ISGs in living cells results in the emission
of fluorescent signals (Figure 1B) that can be detected by flow
cytometric analysis. The BiFC assay identified 41 ISGs that
potentially interact with the HBx protein (Figure 1C). To further
validate the BiFC results, we conducted a coIP assay. DDB1
was used as a positive control (Hodgson et al., 2012) (Fig-
ure S1A), and two BiFC-negative ISGs (UBA7 and TRIM62)
were used as negative controls (Figure S1B). Under conditions
of overexpression, the BiFC assay may yield some false-positive
results; therefore, 15 ISGs in the BiFC-positive group were not
consistent with our coIP experiment. Finally, the coIP assay
confirmed the results of the BiFC asssay for 26 ISGs in 293T cells
(Figure S1C). We further confirmed the interaction of HBx with
seven ISGs (Figures S2F–S2K) that we found had an inhibitory ef-
fect on HBV replication (Figures S2A–S2D, gray bar; labeled in
red in Figure 1C) in HepG2 cells.
High Induction of TRIM5g in IFN-a Treatment of HBV
Patients Indicates a Better Therapeutic Effect
Asmultiple potent anti-HBV ISGs belonging to the TRIM family of
proteins (including TRIM5g, TRIM38, and TRIM25) were identi-
fied in this study, we further investigated their anti-viral function.
In a very recent study, we showed that TRIM25, which was
induced by type I IFN in an interleukin-27 (IL-27)-dependent
manner, might inhibit HBV replication by promoting IFN produc-
tion (Tan et al., 2018a). Becuase TRIM5g was found to have the
highest induction in response to IFN-a treatment among the 7
potent anti-HBV ISGs tested (Figure 2A), we asked if the induc-
tion of TRIM5g was important in IFN-a treatment of HBV pa-
tients. To answer this question, blood samples of 31 HBV-in-
fected patients collected before or 17 weeks after IFN-a
treatment were assessed for serum levels of ALT, AST, HBeAg
and HBV DNA (Table S1). Our data indicated that IFN-a treat-
ment significantly decreased ALT, AST, HBeAg, and HBV DNA
levels (Figure 2B). Interestingly, after determining the TRIM5g
expression levels in patient peripheral blood mononuclear cells
(PBMCs) at 15 min before or 96 h after IFN-a treatment, we
divided the patients into 2 groups; one group (15 patients) had
low TRIM5g induction and the other (16 patients) had high induc-
tion (Figures 2C). Just as we expected, the high group re-
sponded well to the treatment and exhibited much better out-
comes compared to the group with low TRIM5g induction
(Figure 2E). As a control, we also detected the expression of
Figure 1. Screening of ISGs That Interact
with HBx by BiFC Assay
(A) Schematic illustration of the BiFC assay.
(B) Expression plasmids for YFPc-GBP2 and
YFPc-TRIM62 were transfected individually with
YFPn-HBx plasmid into 293T cells. YFP fluores-
cence intensity was measured 36 h post-trans-
fection. Scale bars represent 100 mm.
(C) A total of 145 YFPc-ISG plasmids were trans-
fected individually with the YFPn-HBx plasmid into
293T cells, and YFP fluorescence was measured
after 36 h by flow cytometry. YFP fluorescence
mean intensity (MFI) of >2 was deemed to signify
interaction with HBx (labeled in orange) and <2
was deemed to indicate absence of any interac-
tion (labeled in green). The positive control (YFPc-
58CUN+YFPn-FNCC) is marked in purple, and the
negative control (YFPc-58CUN or YFPn-FNCC
was transfected individually; MFI, 1) is in blue.
Mean ± SD values from three independent ex-
periments are shown.TRIM22 (Figure 2D), a protein that was shown to inhibit HBV
replication and was associated with good response to IFN treat-
ment in vitro (Lim et al., 2017); however, the induction of TRIM22
was not associated with patient outcomes (Figure 2E). These
findings strongly indicate that high induction of TRIM5g in pa-
tients on IFN-a therapy predicts better outcomes. Collectively,
these results demonstrate the direct co-relation between
TRIM5g expression and efficacy of IFN therapy.
TRIM5g Inhibits HBV Infection and Replication by
Targeting HBx
The above results have demonstrated that TRIM5g interacted
with HBx and inhibited HBV replication. Also, similar to IFNa
treatment, the inhibition of HBV replication by TRIM5g showed
a kinetics correlation (Figures S3A–S3C). BMS-200475, an
HBV replication inhibitor, significantly inhibited both wild type
(WT) and DX HBV replication in HepG2 cells (Figure S3D). Inter-
estingly, we found that the inhibitory effect of TRIM5g on HBV
replication was much less significant in the pHBV1.2-DX-
plasmid-transfected HepG2 cells compared with that in
pHBV1.2-WT-plasmid-transfected cells (Figure 3A), which indi-
cates that HBx might be the target of TRIM5g. To verify the re-
sults in the HBV infection system, we performed the infection
assay in HepG2-NTCP cells, which can support HBV infection
because of the high expression of NTCP (Figure S3E) (Yan
et al., 2012). HBsAg was detected in HBV-infected HepG2-
NTCP cells by immunofluorescence (Figure S3F). HepG2-
NTCP cells were infected with lenti-ctrl or TRIM5g; 16 h later,Cell Reportsthe cells were infected with HBV (as
shown in Figure 3B), and as expected,
HBV DNA, pgRNA, and HBsAg expres-
sions in the TRIM5g-overexpressed
HepG2-NTCP cells were significantly in-
hibited in the cells infected with HBV (Fig-
ures 3C and S3G). Furthermore, we in-
tended to verify the effect of TRIM5g in
the IFN-a-mediated inhibition of HBVin vitro and found that HepG2-NTCP WT or TRIM5a/g knockout
(KO) cells were infected by HBV with or without IFN-a treatment,
as we expected, TRIM5a/g KO enhanced HBV replication, and
the inhibitory effects of IFN-a in HBV replication was significantly
reduced in TRIM5a/g KO HepG2-NTCP cells (Figures 3D, S3H,
and S3I), which suggested the indispensiable role of TRIM5g in
IFN-a-mediated inhibition of HBV replication. These results indi-
cated the essential role of TRIM5g in inhibiting HBV infection
and replication by targeting HBx.
TRIM5g Specifically Promotes HBx Degradation by K48-
Linked Ubiquitination
We further investigated the mechanisms that underlie the anti-
viral effect of TRIM5g mediated through HBx. Most of the
TRIM proteins are RING-type E3 ligases, which recruit ubiquitin
to target proteins for degradation (Hatakeyama, 2011). There-
fore, TRIM5g was co-transfected with HBV protein expression
plasmids (HBV Core, Pre-core, S, or X) into 293T cells. The re-
sults showed that TRIM5g specifically and strongly promotes
HBx degradation but not the other HBV proteins (Figure 4A).
We also found that out of the proteins that were tested (including
TRIM38), only TRIM5g inhibited HBx expression (Figure 4B).
For additional testing, we, therefore, selected TRIM5a, which is
another well-characterized member of the TRIM5 family with
known anti-viral function and has the same N-terminal region
(1–298 amino acids) as that of TRIM5g (Battivelli et al., 2011).
We found that TRIM5g but not TRIM5a promoted HBx degrada-
tion (Figure 4C). In addition, TRIM5g-induced HBx degradation29, 3551–3563, December 10, 2019 3553
Figure 2. Higher TRIM5g Induction Indicates a Better Therapeutic Outcome of HBV Patients Undergoing IFN-a Treatment
(A) HepG2 cells were treated with IFN-a (10 ng/mL) or untreated; qPCR was performed to analyze the mRNA expression level of 7 ISGs, as indicated.
(B) Blood samples of 31 HBV-infected patients before and 17 weeks after IFN-a treatment were collected for ALT, AST, HbeAg, and HBV DNA detection.
(C and D) PBMCs from HBV patients before or after IFN treatment were isolated and subjected to RNA extraction; qPCR was performed to evaluate the TRIM5g
(C) or TRIM22 (D) mRNA level.
(E) Seventeen weeks after IFN treatment, the outcome of the two HBV-infected patients groups (TRIM5g high or low, TRIM22 high or low) were analyzed
by comparing the AST, ALT, HbeAg, and HBV DNA levels. Mean ± SD values from three independent experiments are shown. *p < 0.05, **p < 0.01, ***p < 0.001,
#p > 0.05.was confirmed by immunofluorescence (Figure 4D). To further
confirm the results, HepG2 cells with KO of both TRIM5g and
TRIM5a were generated using the CRISPR/Cas9 system (Fig-
ure 4E; Figure S4A). As expected, HBx expression was signifi-3554 Cell Reports 29, 3551–3563, December 10, 2019cantly elevated in HepG2 cells that lacked TRIM5a/g after trans-
fection of HBx (Figure 4E, line 1 and 5). In addition, degradation
of HBx by IFN-a stimulation was almost blocked in TRIM5a/gKO
HepG2 cells (Figure 4E). These results indicated that TRIM5g
Figure 3. TRIM5g Inhibits HBV Infection and Replication by Targeting HBx
(A) HepG2 cells were co-transfected with constructs expressing TRIM5g proteins and either pHBV1.2 WT or DX, as indicated. After 72 h, cells and supernatant
were harvested and subjected to qPCR or ELISA.
(B) Scheme of HBV infection.
(C) HepG2-NTCP cells were infected with lentiviral-ctrl or lentiviral-TRIM5g for 16 h, and later, cells were washed with PBS and inoculated for 24 h with HBV. After
infection, cells were washed three times with PBS and were maintained for another 9 days; the medium was changed every 2 days. The supernatant and cells
were collected for detection of HBV DNA, pgRNA, and HBsAg by qPCR or ELISA.
(D) HepG2-NTCPWT or TRIM5a/g KO cells were infected with HBV for 24 h with or without IFN-a treatment (10 ng/mL) and analyzed as in (C). Mean ± SD values
from three independent experiments are shown. *p < 0.05, **p < 0.01, ***p < 0.001.could specifically trigger HBx degradation and that it plays an
important role in IFN-induced HBx degradation. TRIM5 was
reported to be involved in autophagy (Keown et al., 2018); how-
ever, TRIM5g-mediated HBx degradation was not affected by
3-MA (3-Methyladenine), the autophagy inhibitor (Figure S4B).
The TRIM family is a diverse family of RING-finger-domain-con-
taining proteins that mediate post-translational modifications,
such as protein ubiquitination, which are involved in a variety
of cellular functions (Kawai and Akira, 2011). To further investi-
gate the mechanisms involved in TRIM5g-mediated HBx degra-
dation, we evaluated the HBx ubiquitination by TRIM5g. As ex-
pected, degradation of HBx by TRIM5g was rescued by the
proteasome inhibitor MG132 but not by Z-VAD, the caspase in-hibitor (Figure 4F); furthermore, the HBx mRNA level was not
affected by TRIM5g (Figure S4C). In addition, the coIP assay
confirmed that TRIM5g promotes HBx ubiquitination; moreover,
we found that enhanced TRIM5g-mediated HBx ubiquitination
was linked to K48 but not to K63 in both 293T and HepG2 cells
(Figures 4G and 4H; Figure S4D). These findings suggested
that TRIM5g may promote HBx K48-linked ubiquitination and
degradation by the proteasome pathway.
TRIM5g BBox Domain Is Responsible for the Interaction
and Degradation of HBx
To identify the TRIM5g domain that interacts with HBx, individ-
ual plasmids encoding truncated TRIM5g (as shown inCell Reports 29, 3551–3563, December 10, 2019 3555
Figure 4. TRIM5g Specifically Promotes HBx Degradation
(A) 293T cells were co-transfected with constructs expressing FLAG-HBV proteins and either GFP-TRIM5g or EV as indicated. After 36 h, cells were harvested
and whole-cell lysates were subjected to immunoblotting using anti-FLAG, anti-GFP, or anti-Tubulin antibody.
(B) 293T cells were co-transfected with FLAG-HBx and either GFP-TRIM5g, -USP2, -TRIM38, -UBE3A, or -EV expression plasmids as indicated and were
analyzed as in (A).
(C) HepG2 cells were co-transfected with plasmids expressing FLAG-HBx and either HA-TRIM5g or TRIM5a or hemagglutinin (HA) empty vector as indicated,
and cells were collected 28 h after transfection. Whole-cell lysates were immunoblotted with antibodies as indicated.
(D) FLAG-HBx and either HA-TRIM5g or HA empty vector was transfected into HepG2 cells as indicated; 48 h later, cells were fixed in acetone-methanol and
subjected to immunofluorescence staining analysis using FLAG and HA antibodies. Scale bars represent 20 mm.
(E) TRIM5a and TRIM5gwere both knocked out in HepG2 cells by CRISPR/Cas9 technology; WT or TRIM5a/g KOHepG2 cells were transfected with FLAG-HBx;
and 24 h later, cells were treated with IFN-a as indicated. Post-treatment, whole-cell lysates were immunoblotted with the indicated antibodies.
(legend continued on next page)
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Figure 5. BBox Domain of TRIM5g Is Indis-
pensable for TRIM5g-Induced HBx Degra-
dation
(A) Diagrams of mutant TRIM5g constructs.
(B) 293T cells were co-transfected with FLAG-HBx
and TRIM5g-derived constructs or EV as indi-
cated, andwhole-cell lysateswere immunoblotted
with anti-FLAG, HA, or GAPDH antibodies.
(C) 293T cells were transfected as indicated; 28 h
later, coIP was carried out, and cell lysates and
precipitated samples were analyzed by immuno-
blotting using an anti-FLAG or anti-HA antibody.
(D) 293T cells were transfected with glutathione
S-transferase (GST)-BBox, flag-HBx, or EV as
indicated and were subjected to coIP analysis
as in (C).
(E) 293T cells were co-transfected with FLAG-HBx
and GST-BBox or HA-TRIM5g plasmids and
analyzed as in (B).
(F) HepG2 cells were transfected with FLAG-HBx,
HA-Ub, GST-Bbox, or GST-EV plasmids as indi-
cated; 24 h later, cells were treatedwithMG132 for
8 h, collected, and subjected to coIP analysis.
Data are representative of at least three indepen-
dent experiments.Figure 5A) were co-transfected with the HBx expression vector
in 293T cells. The RING domain of TRIM proteins is known
to confer E3 ligase activity by facilitating an interaction with
E2 enzymes (Rajsbaum et al., 2014). Interestingly, deletion of
the TRIM5g RING domain (DR) did not affect HBx degradation,
whereas deletion of both the RING and BBox domains (DRB)
abolished the ability of TRIM5g to degrade HBx (Fig-
ure 5B). Consistent with this finding, the interaction between
HBx and TRIM5g was disrupted by RB deletion (DRB) but not
by RING deletion (DR) (Figure 5C). In addition, we demon-
strated that the BBox domain is sufficient to interact with HBx
(Figure 5D) and induce HBx degradation by ubiquitination (Fig-
ures 5E and 5F). These results indicated that the TRIM5g BBox
domain is indispensable for the interaction between TRIM5g
and HBx.(F) HepG2 cells were co-transfected with HA-TRIM5g and FlAG-HBx as indicated; 24 h later, cells were treate
for immunoblotting with antibodies as indicated.
(G) 293T cells were co-transfected with HA-Ub and FLAG-HBx, with or without GFP-TRIM5g; 24 h later, cells
subjected to coIP analysis. Cell lysates and precipitated samples were subjected to immunoblot analysis us
(H) 293T cells were co-transfected with K48 or K63-Ub and Flag-HBx, with or without GFP-TRIM5g; 24 h later
cells were collected and analyzed as in (G). Data are representative of at least three independent experimen
Cell ReportsTRIM5g Promotes HBx K95 Site
Ubiquitinatin by Interacting with
the C Terminus of HBx
It has been previously shown that the HBx
region encompassing amino acid residues
88–100 and, particularly, Arg96 is critical
for HBx interaction with some target pro-
teins (Hodgson et al., 2012). To map the
HBx region responsive for interaction
with TRIM5g, we deleted the amino acid
residues 88–100 ormade aR96Emutation(Figure 6A); surprisingly, we found that neither of these two muta-
tions affect HBx interaction with TRIM5g (Figure 6B). Therefore,
we generated three truncated HBx constructs and peformed
coIP of extracts from 293-T cells co-transfected with TRIM5g
and a truncated HBx construct. The results indicated that X3
strongly and X2 partialy interacts with TRIM5g (Figure 6C). To
further map the TRIM5g interacting region of HBx, we truncated
X2 by deleting amino acids 88–100 and divided X3 into two small
peptides. CoIP results showed that X3b is likely responsible for in-
teracting with TRIM5g (Figure 6D). To further confirm these re-
sults, the X2b, X3b, or both fragments were deleted from the
full-length HBx protein. The results indicated that deleting the
X3b but not the X2b fragment of HBx disrupts its interaction
with TRIM5g (Figure 6E) and protects it from TRIM5g-mediated
degradation (Figure 6F). Interestingly, we noticed that afterd with 10 mMMG132 or Z-VAD for 8 h and collected
were treated with MG-132 as indicated for 8 h and
ing the indicated antibodies.
, cells were treated with MG132 (10 mM) for 8 h; and
ts.
29, 3551–3563, December 10, 2019 3557
Figure 6. TRIM5g Interacts with the C Terminus of HBx and Promotes HBx K95 Site Ubiquitination
(A) Diagram of mutant HBx constructs. the numbers indicate the amino acids in the HBx constructs.
(B–E) 293T cells were co-transfected with the expression vectors for Flag-TRIM5g and GST-HBx WT or mutants (B, R96E, Del; C, X1, X2, X3; D, X2a, X2b, X3a,
X3b; E, X3bD, DD, X2bD) or EV as indicated. After 28 h, cells were harvested, coIP with FLAG-HBx, and cell lysates and precipitated samples were analyzed by
immunoblotting with the indicated antibodies.
(F) HBx WT or truncations were co-transfected with TRIM5g or EV into HepG2 cells; 28h later, cell lysates were subjected to immunoblot analysis using the
indicated antibodies.
(G) Plasmids of expression of HBx WT, K90R, or K95R were co-transfected with TRIM5g or EV into HepG2 cells; 28h later, cell lysates were subjected to
immunoblot analysis using the indicated antibodies.
(H) HepG2 cells were co-transfected with the expression vectors for HA-TRIM5g, HA-Ub, and FLAG-HBx WT or mutants as indicated; 28h later, cells were
harvested and coIP with FLAG-HBx, and cell lysates and precipitated samples were analyzed by immunoblotting with the indicated antibodies. Data are
representative of at least three independent experiments.deletion of amino acid residues 88–100, HBx will not be degra-
dated by TRIM5g (Figure 6B), which indicated that this region
might be responsible for ubiquitination. Thus, mutation was per-
formed to the two lysines in this region, and interestingly, HBx
was no longer degradated by TRIM5g after K95 mutation but
not K90mutation (Figure 6G). In addition, TRIM5gwill not promote
the ubiquitination of HBx after K95R mutation (Figure 6H). Taken3558 Cell Reports 29, 3551–3563, December 10, 2019together, these results clearly demonstrated that TRIM5g inter-
acted with the C terminus (129–155) of HBx and triggered its
degradation by promoting HBx K95 site ubiquitinatin.
TRIM5g Recruits TRIM31 for HBx Degradation
We showed that E3 ubiquitin ligase activity of TRIM5g is not
indispensable for degradation of HBx. Therefore, another E3
Figure 7. TRIM5g Recruits TRIM31 to Degradate HBx
(A) HepG2 cells were co-transfected with FLAG-HBx and HA-TRIM31 or HA empty vector plasmids; 36 h later, cells were left untreated or were treated with
MG132 (10 mM) or Z-VAD (10 mM) as indicated. Cells were harvested after treatment, and whole-cell lysates were immunoblotted with the indicated antibodies.
(B) HepG2 cells were transfected with FLAG-HBx, HA-Ub, HA-TRIM5g, or TRIM31 expression plasmids as indicated; 24 h later, cells were treatedwithMG132 for
6 h and were collected and subjected to coIP analysis.
(C) HepG2 cells were transfected with FLAG-HBx or co-transfected with TRIM31 plasmids (WT or mutant); 36 h later, cells were harvested and analyzed as in (A).
(D) HepG2 WT or TRIM31 KO cell lysates were immunoblotted with TRIM31 or Tubulin antibody.
(E)HepG2WTorTRIM31KOcellswere transfectedwithFLAG-HBxwithorwithout theTRIM5gexpressionvector; 28h later, cellswerecollectedandanalyzedas in (A).
(F) WT HepG2 cells or TRIM31 KO cells were transfected as indicated; 28 h later, cells were collected and analyzed as in (A).
(G and H) Expression vectors for HA-TRIM5g (G) or GST-BBox (H) were co-transfected into 293T cells with or without FLAG-TRIM31; 36 h later, cells were
subjected to coIP using FLAG-TRIM31. Immunoblot analyses were carried out using anti-FLAG, anti-HA, or anti-GST antibody.
(I) 293T cells were transfected with FLAG-HBx, HA-TRIM5g, or HA-TRIM31 expression plasmids as indicated; 24 h later, cells were treated with MG132 (10 mM)
for 8 h and subjected to coIP analysis. Immunoblotting was carried oout using an anti-FLAG or anti-HA antibodies. Data are representative of at least three
independent experiments.
(J) HepG2WT or TRIM31 KO cells were transfected with pHBV1.3 plasmids or together with TRIM5g or TRIM31 expression plasimds as indicated; 72 h later, the
supernatant was tested for HBeAg and HBsAg content using ELISA. Mean ± SD values from three independent experiments are shown. **p < 0.01.
(K) HepG2 WT or TRIM31 KO cells were transfected with pHBV1.3 plasmids; 24 h later, cells were treated with IFN-a (10ng/ml) or untreated. After another 48 h,
qPCR was performed to evaluate the HBV pgRNA and DNA levels. Mean ± SD values from three independent experiments are shown. *p < 0.05, **p < 0.01.protein may be responsible for HBx degradation and TRIM5g
may possibly act as an adaptor in this process. Several TRIM
proteins have been shown to inhibit HBV infection (Zhang
et al., 2013), of which TRIM31 has recently emerged as an attrac-
tive candidate that possesses E3 ubiquitin ligase activity (Koza-kova et al., 2015; Ra et al., 2016; Song et al., 2016). Consistent
with this postulation, our data indicated that akin to TRIM5g,
TRIM31 also promoted HBx degradation and that MG132 in-
hibited this process (Figure 7A); furthermore, both TRIM5g
and TRIM31 promoted HBx ubiquitination in HepG2 cellsCell Reports 29, 3551–3563, December 10, 2019 3559
(Figure 7B). In addition, C31 and H33 double mutation in the
RING domain has been shown to block the E3 ligase activity of
TRIM31 (Kozakova et al., 2015), We found that this double
mutation abolished TRIM31-mediated HBx degradation (Fig-
ure 7C). This indicated that unlike TRIM5g, TRIM31 functioned
as an E3 ligase in HBx degradation. Therefore, TRIM31 could
be the E3 ubiquitin ligase that causes the ubiquitination and
degrdation of HBx. To investigate the role of TRIM31 in
TRIM5g-mediated HBx degradation, we used CRISPR/Cas9
technology and generated TRIM31-KO HepG2 cells (Figure 7D;
Figure S5). Interestingly, we found that TRIM5g-mediated
HBx degradation was impaired in TRIM31 KO cells (Figure 7E)
but was restored upon reconstitution of TRIM31 in KO cells by
using a plasmid expressing WT TRIM31 (Figure 7F). Therefore,
it appeared that TRIM31 is indispensable for TRIM5g-mediated
HBx degradation. Next, we investigated whether TRIM5g re-
cruits TRIM31 to degrade HBx. Our data indicated that both
TRIM5g and its BBox domain could interact with TRIM31 (Fig-
ures 7G and 7H) and form a TRIM31-TRIM5g-HBx complex (Fig-
ure 7I). In addition, TRIM31 KO disrupted TRIM5g-mediated
inhibition of HBV (Figure 7J) and also inhibited the IFN-a-medi-
ated inhibition of HBV replication (Figure 7K). Therefore, in
response to HBV infection, TRIM5g might recruit TRIM31 and
form a complex with HBx, which leads to proteasomal degrada-
tion of HBx.
DISCUSSION
Although IFN is widely used for treatment of HBV in clinical
settings, the underlying mechanisms responsible for the antiviral
effects of IFN against HBV are not fully understood. In the pre-
sent study, we hypothesized that the anti-viral effect of IFN is
at least partially dependent on the interaction between ISG
products and HBV proteins. Therefore, we screened 145 ISGs
that potentially interact with HBx to characterize the molecular
mechanism of IFN-mediated inhibition of HBV through direct
HBx-ISG protein-protein interactions. We identified 7 ISGs
that significantly inhibited HBV replication by interacting with
HBx. Moreover, we found that TRIM5g inhibited HBV replication,
likely by directing TRIM31 toward HBx K48 chain ubiquitination
and degradation on the K95 ubiquitin site. An important
finding of this study was that induction of high expression
levels of TRIM5g in HBV patients treated with IFN-a might
indicate a better therapeutic effect and that BBOX may be a po-
tential candidate for development of therapeutic agents that
target HBx.
Activation of IFN production is one of the earliest transcrip-
tional responses to viral infection. Interestingly, after HBV
infection, INF signaling was reported to be impaired by HBx
through upregulation of the suppressor of cytokine signaling
3 and protein phosphatase 2A (Tsunematsu et al., 2016). In
addition, HBx was also shown to inhibit IFN-induced TRIM22
production by single CpG methylation in the 50 UTR of
TRIM22 (Lim et al., 2017), which demonstrates the importance
of HBx in combating IFN signaling. In the data shown in Fig-
ure S1, several ISG proteins (e.g., Bach1 and IFITs) were
much less expressed in the HBx-transfected cells, although
we transfected the same amount of plasmids, which indi-3560 Cell Reports 29, 3551–3563, December 10, 2019cated that those proteins might be degradated by HBx. This
finding is consistent with a report that showed lower expres-
sions of IFIT families in HCC tissues than those in normal
tissues (Yang et al., 2017). Moreover, HBx was recently shown
to hijack the cellular DDB1-containing E3 ubiquitin ligase to
target the Smc complex Smc5/6 for degradation, which, in
turn, facilitates HBV replication (Murphy et al., 2016). As a
key viral regulatory protein known to play a central role in
HBV infection, replication, pathogenesis, and, possibly, carci-
nogenesis (Murakami, 2001), HBx is essential for maximal
HBV replication and development of HCC (Berasain and Le-
chel, 2017; Keasler et al., 2007). HBV X region mutations
were shown to be associated with clinical severity (Yeh
et al., 2010). Direct interaction between ISGs and viral proteins
plays an important role in restricting viral replication (Ja¨ger
et al., 2011; Stremlau et al., 2004). Therefore, identification
of ISGs that directly interact with HBx may shed some light
on the mechanism by which type I IFN inhibits HBV. We iden-
tified 7 ISGs (GBP2, PVRL4, CBFb, TRIM38, TRIM5g, TRIM25,
and Gadd45g) that interact with HBx and inhibit HBV replica-
tion. GBP2 has been previously shown to inhibit the replication
of vesicular stomatitis virus (VSV) and encephalomyocarditis
virus (EMCV) (Carter et al., 2005). The V domain of PVRL4
has been shown to be critical for cell entry and intercellular
spread of canine distemper virus (CDV) (Delpeut et al.,
2014). Interestingly, CBFb was shown to be hijacked by HIV
viral infectivity factor (VIF) to degrade APOBEC3G and pro-
mote HIV-1 infection (Ja¨ger et al., 2011); conversely, it was
found to play an opposite role with respect to HBV replication
in the present study, and our further study on CBFb suggested
CBFb inhibited HBV replication by blocking the HBx-Smc6
interaction Xu et al., 2019). Gadd45g acts as a tumor suppres-
sor gene by blocking S and G2/M cell cycle checkpoints (Vair-
apandi et al., 2002). To the best of our knowledge, there are
only a few reports on the role of the above five proteins in
HBV inhibition. Therefore, characterization of the mechanisms
by which these ISGs combat HBV replication may facilitate the
development of therapeutic strategies.
Interestingly, in addition to the four abovementioned ISGs, the
rest of the most potent anti-HBV ISGs were Tripartite motif
(TRIM) proteins, including TRIM5g, TRIM38, and TRIM25.
TRIM proteins are involved in multiple cellular functions,
including antiviral activity (Nisole et al., 2005). TRIM E3 ubiquitin
ligases, a subset of the TRIM family, have been shown to restrict
viral replication by targeting viral proteins directly (Rajsbaum
et al., 2014). TRIM25 has been shown to inhibit HBV replication
(Zhang et al., 2013). In our recent study, TRIM25, which was
induced by type I IFN in an IL-27-dependent manner, was shown
to inhibit HBV replication by promoting IFN production (Tan et al.,
2018a). In contrast, TRIM38 was shown to downregulate TLR-
mediated immune responses by targeting TRIF and TNF-recep-
tor-associated factor 6 (Zhao et al., 2012), which explains its
adverse role in counteracting viral replication. In the present
study, we found that TRIM5g can specifically promote HBx
degradation by ubiquitination on the K95 ubiquitin site; we also
found that the Ring domain responsible for the ligase activity is
not essential for degradation of HBx by TRIM5g and that only
the BBox of TRIM5g, which is a 40 amino acid peptide, is enough
to trigger HBx degradation. HBx has been shown to interact with
multiple proteins, including the ubiquitin proteasome system
(UPS) components (Minor and Slagle, 2014), and some deubi-
quitinases (DUBs) target HBx and protect it from proteasome
degradation. It is possible that the interaction of TRIM5g with
other E3 ligase proteins results in HBx degradation. TRIM31,
which is also reported to inhibit HBV replication (Zhang et al.,
2013), has been shown to possess ubiquitin ligase activity (Liu
et al., 2016; Song et al., 2016), and TRIM31 RING-finger muta-
tions (C31A andH33A) have been shown to abolish the ligase ac-
tivity of TRIM31 (Sugiura and Miyamoto, 2008). We have shown
that overexpression of TRIM31 leads to HBx degradation. In
addition, knocking out TRIM31 blocked the degradation of
HBx by TRIM5g, which indicated that TRIM31was indispensable
for TRIM5g-induced HBx degradation. We further confirmed that
TRIM31 interacts with TRIM5g and HBx and forms a TRIM31-
TRIM5g-HBx complex. Our findings are consistent with a very
recent report that showed that TRIM31 promotes NLRP3 K48-
linked polyubiquitination and proteasomal degradation (Song
et al., 2016). Nevertheless, further investigations are required
to explore the exact mechanism underlying the HBx degradation
by TRIM31.
In addition, we have shown that TRIM5g but not TRIM5a can
promote HBx degradation. TRIM5g has a shorter and distinct
C terminus than its isoform alpha, whichmay support the distinct
molecular structure required for interaction with HBx. Interest-
ingly, overexpression of TRIM5g has been shown to be devoid
of antiviral activity against N-MLV and HIV-1 by inhibiting the ac-
tivity of TRIM5a (Stremlau et al., 2004) (Battivelli et al., 2011).
Similarly, it will be easy to understand that the formation of
the TRIM5a/g dimer might inhibit the degradation of HBx by
TRIM5g and that overexpression of TRIM5a might promote
HBV replication by offsetting the inhibitory effects of TRIM5g.
With sgRNA targeting theN terminus of TRIM5g, the BBox region
that we verified as the interaction domain with HBx could be
destroyed, but TRIM5a will be also knocked out; thus it is
difficult to a generate a cell line with TRIM5g KO only. Neverthe-
less, overexpression of WT TRIM5g but not TRIM5a in HepG2
cells resulted in HBx degradation and HBV replication inhibition,
which confirmed the critical role of TRIM5g in inhibiting HBV
replication. It would be very interesting to fully understand the
mechanism responsible for the differential function of these
two molecules.
Collectively, we have demonstrated a crucial role for
TRIM5g and TRIM31 in promoting HBx degradation and
have shown that a short peptide is sufficient to trigger HBx
degradation. In addition, induction of high expression levels
of TRIM5g in HBV patients undergoing IFN-a therapy was
associated with better outcomes. These findings may facilitate
the development of therapeutic agents for the treatment of
patients with IFN-resistant HBV infection, and TRIM5g may
serve as a useful biomarker to predict IFN-a therapeutic
response. Nevertheless, because upregulation of the down-
stream ISGs is a key driver of the efficacy of IFN therapy, it
will be interesting to investigate if HBV could regulate TRIM5g
and TRIM31 expression in response to IFN treatment, which
may explain the mechanism of IFN resistance. Further investi-
gation of the molecular mechanisms involved in the IFN-HBVinteraction is required to fully resolve the problem of IFN resis-
tance in HBV-infected patients.STAR+METHODS
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GST Tag Antibody proteintech Cat# 10000-0-AP; RRID:AB_11042316
Monoclonal ANTI-FLAG M2 antibody produced in
mouse
Sigma Cat# F1804; RRID:AB_262044
GAPDH Antibody proteintech Cat# 10494-1-AP; RRID:AB_2263076
b Tubulin Antibody (SAP.4G5) Santa Cruz Biotechnology Cat# sc-58884; RRID:AB_793548
NTCP Polyclonal Antibody Signalway Antibody Cat#41759
HBsAg antibody lifespan biosciences Cat# LS-C67520-1000; RRID:AB_10634869
HRP-Goat Anti-Rabbit IgG(H+L) proteintech Cat# SA00001-2; RRID:AB_2722564
HRP-Goat Anti-Mouse IgG(H+L) proteintech Cat# SA00001-1; RRID:AB_2722565
Goat anti-mouse IgG (H+L), Cy3 conjugate proteintech Cat# SA00009-1; RRID:AB_2814746
Goat anti-rabbit IgG (H+L), Cy3 conjugate proteintech Cat# SA00009-2
Goat anti-rabbit IgG (H+L), FITC conjugate proteintech Cat#SA00003-2
Goat anti-mouse IgG (H+L), FITC conjugate proteintech Cat#SA00003-1
Biological Samples
HBV patient venous blood samples The First Hospital of Jilin University N/A
Chemicals, Peptides, and Recombinant Proteins
ANTI-FLAG M2 Affinity Gel Sigma A2220
Z-VAD-FMK promega G7232
Protease inhibitor Roche 11697498001
MG132 Sigma M7449
BMS-200475 MedChemExprss HY-13623A
3-MA MedChemExprss HY-19312
Recombinant Human IFN-a biolegend 592706
Critical Commercial Assays
HBeAg detection Kit Kehua shengwu N/A
HBsAg detection Kit Kehua shengwu N/A
Viafect transfection reagent promega E4982
PEG-it Virus Precipitation Solution System Biosciences BY-LV810A-1
lentiviral-ctrl Genecopoeia Lot#: GC12182K1701
lentiviral-TRIM5g Genecopoeia Lot#: GC05212K1804
EasyPure Viral DNA/ RNA Kit Transgen ER201-01
EasyPure RNA Kit Transgen ER101-01
TransScript All-in-One First-Strand cDNA Synthesis
SuperMix for qPCR(One-Step gDNA Removal)
Transgen AT341-02
E.Z.N.A. Endo-Free Plasmid Mini Kit I Omega D6948-02
pEASY-Blunt Cloning Kit Transgen CB101-02
Faststart Universal SYBR Green Master(ROX) Roche #04913914001
Cell Counting Kit-8 (CCK-8) Bimake B34302
(Continued on next page)
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Protease Inhibitor Cocktail (EDTA-Free, mini-Tablet) Bimake B14012
FastDigest XbaI Thermo Sci FD0684
Experimental Models: Cell Lines
HepG2 ATCC HB-8065
HepG2-NTCP This paper
293T ATCC ACS-4500
Oligonucleotides
See Tables S2 and S3 N/A N/A
Recombinant DNA
HBx wt expression plasmid This paper N/A
HBx K90R expression plasmid This paper N/A
HBx K95R expression plasmid This paper N/A
HBx R96E expression plasmid This paper N/A
HBx 88-100 deletion expression plasmid This paper N/A
TRIM5g and the truncations expression plasmids This paper N/A
pHBV1.3 plasmid Lishan Su lab of University of North
Carolina at Chapel Hill
N/A
pHBV1.2 WT and pHBV1.2 DX plasmids Qiang Deng lab of Fudan University N/A
GFP-ISGs expression plasmids Cheng lab in UCLA N/A
Software and Algorithms
Prism version 5 GraphPad Software https://www.graphpad.comLEAD CONTACT AND MATERIALS AVAILABILITY
Plasmids and cell lines generated in this study will be made available under a standard material transfer agreement. Requests for
resources and reagents should be directed to andwill be fulfilled by the Lead Contact, Genhong Cheng (GCheng@mednet.ucla.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Thirty one HBV-infected patients were enrolled in this study (Table S1). Naive chronic hepatitis B patients (age: 18-65, serum HBsAg
detectable for > 6 months) undergoing clinical IFNa2a treatment were enrolled into this study. Venous blood samples (5ml) were
collected to obtain serum and PBMCs. HBV DNA level was detected using Rocheˈs COBAS TaqMan kit. Liver function, as well as
biochemical parameters, were tested by an auto-matic biochemical instrument. Tests were conducted at the Hepatology Depart-
ment of the First Hospital of Jilin University, Changchun, China. The study protocol was approved by the IRB of Jilin University,
the First Hospital.
Human Embryonic Kidney 293T (HEK293T) cells, HepG2 cells, and HepG2-NTCP cells were maintained in DMEM containing 10%
inactivated fetal bovine serum, penicillin (100 IU/mL) and streptomycin (100 mg/mL) and incubated at 37C with 5% CO2.
METHOD DETAILS
Infusion cloning
The expression construct of TRIM5g, TRIM5a, TRIM31, HBx, and TRIM5g truncations were generated by cloning the coding region
sequence of relative human genes into VR1012 vector with Flag, HA or GST tag according to the instruction of EASY-Uni Seamless
Cloning kit (TransGen, Beijing, China). The YFP constructs were generated by inserting half of the YFP coding region sequence into
the C-terminal of ISGs expression plasmids and the other half into the N-terminal of the HBx expression plasmid. Site directed muta-
genesis of TRIM5g and TRIM31 was generated by Quik-Change PCR (TransGen, Beijing, China). Primers are listed in Table S2.
Flow cytometry
Cells were collected by trypsinization, fixed in 2% paraformaldehyde, and analyzed on BD FACS Calibur flow cytometer (BD Biosci-
ences, USA). HBV-YFP was quantified as the product of percent GFP-positive population and geometric mean of the fluorescence
index (MFI), and normalized to that of the vector.Cell Reports 29, 3551–3563.e1–e3, December 10, 2019 e2
Total RNA and HBV DNA Extraction and Quantitative Real-time PCR
Total RNAwas extracted using TRIZOl (Invitrogen, San Diego, CA, USA) and then converted to first-strand cDNA using Superscript III
transcriptase (Invitrogen San Diego, CA, USA). HBV DNAwas isolated from the whole cell-lysate or culture supernatant according to
the kit instructions (TransGen, Beijing, China). GAPDH was used as an internal control; quantitative real-time PCRwas carried out as
described previously (Tan et al., 2018a). The sequences of gene-specific primer used for qPCR are shown in Table S3.
Co-immunoprecipitation and Western Blot Analysis
Cells were lysed 24–48 h after transfection of expression plasmids using 50 mM Tris–HCl, pH 8.0, 150 mMNaCl, 1% NP-40 contain-
ing cocktail inhibitors (Roche, USA). For immunoprecipitation, lysates were incubated overnight with ANTI-FLAG M2 Affinity Gel
(Sigma, USA). Immunoblotting was carried out as described previously (Tan et al., 2018a). Briefly, cells were collected and lysed
by adding RIPA lysis buffer together with Protease/Phosphatase Inhibitor Cocktail on ice for 30 min and by tapping tubes every
10 min. Protein concentration was quantified by Coomassie Plus protein assay Reagent (Thermo Scientific, Rockford, IL, USA).
The quantification of immunoblotting band intensity was carried out with ChemiDoc XRS+ Molecular Imager software (Bio-Rad, Phil-
adelphia, PA, USA). Samples were separated by SDS-PAGE and transferred to PVDF membranes. After blocking in TBS containing
0.1% Tween-20 and 5% skim-milk, the blots were probed with relative antibodies.
Immunofluorescence
HepG2 cells were transfected with Flag-HBx plasmids or together with HA-TRIM5g plasmids; 48 hours later, cells were fixed in
acetone-methanol (1:1) at 37C for 10 min. Subsequently, cells were washed with PBS and blocked with 5% BSA in PBST for 1
h, incubated with Flag(Mouse) and HA(Rabbit) antibody at 37C for 1 h, washed in PBS, and then incubated with goat anti-mouse
IgG conjugated with FITC or both Cy3(rabbit) and FITC(mouse) conjugated IgG (Proteintech). Cells were washed with PBS and
observed under a fluorescence microscope.
ELISA
HepG2 Cells weremock transfected or transfected with ISG-expression plasmids together with pHBV1.3-HBV expression plasmids.
Supernatant was collected after 72 hours, and the supernatant from HBV infected HepG2-NTCP cells was collected after 9 days for
analysis by ELISA to detect the levels of HBeAg and HBsAg (Kehua Shengwu, China).
CRISPR / Cas9 Knockout
HepG2 or 293T cells were seeded in 24 well plates; 16 h later, two plasmids, one expressing Cas9 with TRIM5a/g or TRIM31 sgRNA
(FG-EH-Cas9-2F-PPW) and the other carrying a puromycin resistant gene (PL-GFP-IP), were co-transfected into HepG2 cells using
ViaFect transfection reagent (Promega). At 36 h after transfection, cells were either selected by adding puromycin at a concentration
of 2 mg/mL or collected for immunoblotting with specific TRIM5g, TRIM5a or TRIM31 antibodies. Two days later, live cells were sorted
into a 96-well plate at a density of 1 cell per well using a BD FACSAria. Immunoblotting was performed again to determine the level of
gene editing efficiency after the clonal expansion and DNA sequencing was performed to verify the edited genes. SgRNAs are listed
in the Table S2.
HBV infection assay
Serum from HBV patients with different virus strains (HBV DNA copies > 107) was collected and whole virus were concentrated using
a PEG-it Virus Precipitation Solution (System Biosciences, USA). HepG2-NTCP cells were infected with lentiviral-ctrl (Lot#:
GC12182K1701) or lentiviral-TRIM5g (Lot#: GC05212K1804) for 16 hours, and later, cells were inoculated with the serum produced
virus at anMOI (multiplicity of infection) of 1000 equivalents (Geq) per cell and were cultured in the presence of 4%PEG8000 and 2%
DMSO for 24 h. After infection, cells were washed three times with PBS, and were maintained in DMEMmedium for another 9 days;
themediumwas changed every two days. The supernatant and cells were collected for detection of HBVDNA, pgRNA andHBsAg by
Q-PCR or Elisa; Expressions of TRIM5g were detected by Q-PCR.
QUANTIFICATION AND STATISTICAL ANALYSIS
GraphPad Prism 5 software (GraphPad Software, San Diego, CA) was used for data analysis; a two-tail unpaired t test was used to
assess between-group differences. p value < 0.05 was considered statistically significant.
DATA AND CODE AVAILABILITY
The published article includes all the datasets generated or analyzed during this study.e3 Cell Reports 29, 3551–3563.e1–e3, December 10, 2019
